Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.
暂无分享,去创建一个
R. Bast | L. Norton | C. Desch | R. Winn | N. Kemeny | D. Hayes | P. Ravdin | J. Jessup | H. Fritsche | R. Mennel | S. Taube | G. Locker | L Norton | J. Macdonald | R C Bast | D F Hayes | J M Jessup | J S Macdonald | R J Winn | P. Ravdin | P Ravdin | H Fritsche | G Y Locker | R G Mennel | N E Kemeny | C E Desch | S Taube | Larry Norton | Daniel F. Hayes
[1] W Godolphin,et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. , 1989, Science.
[2] P M Ravdin,et al. Neural Network Analysis of DNA flow cytometry histograms. , 1993, Cytometry.
[3] G. Strauss,et al. Use of tumor markers in lung cancer. , 1994, Hematology/oncology clinics of North America.
[4] L. Demers,et al. Elevated soluble c-erbB-2 antigen levels in the serum and effusions of a proportion of breast cancer patients. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[6] E. Kawasaki,et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. , 1992, Journal of the National Cancer Institute.
[7] H. Burke,et al. Artificial neural networks for cancer research: outcome prediction. , 1994, Seminars in surgical oncology.
[8] D. Hayes,et al. Circulating tumor markers in breast cancer. , 1989, Hematology/oncology clinics of North America.
[9] Lloyd M. Smith,et al. Statement on use of DNA testing for presymptomatic identification of cancer risk. National Advisory Council for Human Genome Research. , 1994, JAMA.
[10] G. Bosl,et al. Serum Tumor Marker Half-Life during Chemotherapy in Patients with Germ Cell Tumors , 1994, The International journal of biological markers.
[11] A Gafni,et al. The practice guidelines development cycle: a conceptual tool for practice guidelines development and implementation. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] S. Friend,et al. Germ-line mutations of the p53 tumor suppressor gene in patients with high risk for cancer inactivate the p53 protein. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[13] Wei Chen,et al. Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. , 1994, Cancer research.
[14] W Wood,et al. Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] R. Sanson-Fisher,et al. Measuring quality of life in cancer patients. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] M. Gail,et al. Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.
[17] F. Freiha,et al. Serum markers in germ cell neoplasms. , 1991, Hematology/oncology clinics of North America.
[18] D. Seigel,et al. Surrogate endpoints in clinical trials: ophthalmologic disorders. , 1989, Statistics in medicine.
[19] S. Rodenhuis,et al. Cellular protoonocogenes are infrequently amplified in untreated non-small cell lung cancer. , 1989, British Journal of Cancer.
[20] L. Carey,et al. A retrospective and prospective study of serial CEA determinations in the early detection of recurrent colon cancer. , 1979, American journal of surgery.
[21] J. Garber. Markers of risk for human malignancies. , 1994, Hematology/oncology clinics of North America.
[22] C. Redmond,et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor-negative tumors. , 1989, The New England journal of medicine.
[23] M. Gent,et al. When is a prognostic factor useful? A guide for the perplexed. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] D. Lin,et al. Evaluating the role of CD4-lymphocyte counts as surrogate endpoints in human immunodeficiency virus clinical trials. , 1993, Statistics in medicine.
[25] M. Skolnick,et al. A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. , 1995, JAMA.
[26] Earlybreastcancertrialistscol,et al. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy 133 randomised trials involving 31 000 recurrences and 24 000 deaths among 75 000 women , 1992, The Lancet.
[27] J. Benda,et al. Preservation of Estrogen Receptor in Paraffin Sections , 1994 .
[28] G M Clark,et al. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. , 1989, The New England journal of medicine.
[29] S. Woolf. Practice guidelines, a new reality in medicine. II. Methods of developing guidelines. , 1992, Archives of internal medicine.
[30] Steven E. Bayer,et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.
[31] I. Ellis,et al. Carcinoembryonic antigen immunocytochemistry in primary breast cancer , 1989, Cancer.
[32] C. L. Callahan,et al. The quality of life. , 1970, Nursing outlook.
[33] H. Burke,et al. Criteria for prognostic factors and for an enhanced prognostic system , 1993, Cancer.
[34] R C Coombes,et al. Immunocytochemical assay for estrogen receptor in patients with breast cancer: relationship to a biochemical assay and to outcome of therapy. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] J. Hanley,et al. The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.
[36] W. McGuire,et al. Prognostic factors and treatment decisions in axillary-node-negative breast cancer. , 1992, The New England journal of medicine.
[37] C. Metz. Basic principles of ROC analysis. , 1978, Seminars in nuclear medicine.
[38] S. George. Statistical considerations and modeling of clinical utility of tumor markers. , 1994, Hematology/oncology clinics of North America.
[39] D. G. Altman,et al. Statistical aspects of prognostic factor studies in oncology. , 1994, British Journal of Cancer.
[40] M. Skolnick,et al. BRCA1 mutations in primary breast and ovarian carcinomas. , 1994, Science.
[41] A. Cruz,et al. Results of a 400‐patient carcinoembryonic antigen second‐look colorectal cancer study , 1985, Cancer.
[42] V. Chinchilli,et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] A. Kaluzny,et al. The National Cancer Institute and guideline development: lessons from the breast cancer screening controversy. , 1994, Journal of the National Cancer Institute.
[44] R. Gelber,et al. Quality of life in clinical trials of adjuvant therapies. International Breast Cancer Study Group (formerly Ludwig Group). , 1992, Journal of the National Cancer Institute. Monographs.
[45] A. Thor,et al. Prognostic significance of p53 overexpression in node-negative breast carcinoma: preliminary studies support cautious optimism. , 1993 .
[46] A. Buzdar,et al. Evaluation of patients after primary therapy for early breast cancer , 1993 .
[47] C. Redmond,et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. , 1989, The New England journal of medicine.
[48] D. Hayes. Tumor markers for breast cancer. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.
[49] C. Taylor,et al. An exaltation of experts: concerted efforts in the standardization of immunohistochemistry. , 1994, Human pathology.
[50] S. Ellenberg,et al. CEA Monitoring Among Patients in Multi‐institutional Adjuvant G.I. Therapy Protocols , 1982, Annals of surgery.
[51] W. McGuire,et al. How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer , 1993, Cancer.
[52] I. Tannock,et al. Goals of palliative cancer therapy. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] H. Rubin,et al. Internists' Attitudes about Clinical Practice Guidelines , 1994, Annals of Internal Medicine.
[54] T. Shawker,et al. A Prospective Analysis of Laboratory Tests and Imaging Studies To Detect Hepatic Lesions , 1982, Annals of surgery.
[55] S. Naber,et al. Detection and quantitation of the human neu oncoprotein , 1991 .
[56] E. Klein. Tumor markers in testis cancer. , 1993, The Urologic clinics of North America.